|1.||Kang, Hyo Jin: 1 article (03/2014)|
|2.||Seong, Yeon-Sun: 1 article (03/2014)|
|3.||Wang, Antai: 1 article (03/2014)|
|4.||Hong, Young Bin: 1 article (03/2014)|
|5.||Liu, Jia-li: 1 article (03/2014)|
|6.||Duong, Hong-Quan: 1 article (03/2014)|
|7.||Yi, Yong Weon: 1 article (03/2014)|
|8.||Gao, Guo-rui: 1 article (03/2014)|
|9.||Meng, Ling-hua: 1 article (03/2014)|
|10.||Cao, Su-fen: 1 article (03/2014)|
06/25/2013 - "In vivo studies indicated a 5-10-fold increased PIK-75 accumulation in the tumor with both the nanosuspension formulations compared to PIK-75 suspension. "
04/01/2010 - "Given that PIK-75 is known to exhibit anti-cancer activity, the findings from this study thus reinforce the cross-therapeutic functionality of potential drugs."
03/01/2014 - "These results suggest that DW series compounds, especially DW09849, selectively targeting PI3Kα with less off-target effects than PIK-75, provide new clues for the design and discovery of new specific PI3Kα inhibitors for cancer therapy. "
01/01/2014 - "PIK-75 is an efficient inhibitor of the PI3-K p110alpha catalytic subunits that suppresses tumor growth, and its effects on immune and autoimmune responses should be studied. "
06/25/2013 - "These results illustrate the opportunity to formulate PIK-75 as a targeted nanosuspension to enhance uptake and cytotoxicity of the drug in tumor."
|2.||Ovarian Neoplasms (Ovarian Cancer)
04/01/2010 - "The efficacy of PIK-75 in attenuating experimental inflammation is mediated, at least in part, due to the downregulation of pertinent inflammatory mediators in the colon. "
04/01/2010 - "Accordingly, we studied the effects of a preferential p110alpha/gamma PI3K inhibitor (compound 8C; PIK-75) in inflammation-based assays. "
01/01/2014 - "These results suggest evidence that p110α mediates esophageal inflammation and that PIK-75 has an anti-inflammatory effect by reducing proinflammatory cytokines on feline esophageal epithelial cultured cells."
03/01/2015 - "Acosta YY, Montes-Casado M, Aragoneses L et al. (2014) Suppression of CD4(+) T lymphocyte activation "in vitro" and experimental encephalomyelitis "in vivo" by the phosphatidyl inositol 3-kinase inhibitor PIK-75. "
01/01/2014 - "Suppression of CD4+ T lymphocyte activation in vitro and experimental encephalomyelitis in vivo by the phosphatidyl inositol 3-kinase inhibitor PIK-75."
|1.||Folic Acid (Vitamin M)
|3.||NF-E2-Related Factor 2
|4.||Proteasome Endopeptidase Complex (Proteasome)
|1.||Heterologous Transplantation (Xenotransplantation)